How do pharma and life sciences brands score for AI search visibility? See which brands are cited by ChatGPT, Perplexity, and Gemini - and which ones are invisible.
Check Your Pharma Brand Score →Showing top 15 of 285 pharma & life sciences brands tracked. View full leaderboard →
Pharma brands score above average compared to most offline sectors, but the stakes are uniquely high - patients and HCPs now use AI assistants to research treatments and suppliers. Brands invisible to AI risk losing consideration at the earliest stage of the purchase journey.
Eight categories: EEAT content (24%), AI citability (18%), AI platform readiness (12%), structured data (12%), technical SEO (12%), brand authority (10%), topical authority (8%) and platform optimisation (4%). Scores run from 0 to 100.
Most pharma & life sciences brands lose points on structured data and AI citability. Adding schema markup, improving Wikipedia/Wikidata presence, and building EEAT content are the highest-leverage fixes.
Enter any domain on SearchScore to get a full breakdown across all eight categories, with actionable quick wins specific to your brand.
Healthcare professionals and patients alike are turning to AI assistants for pharmaceutical information. When a clinician asks about treatment guidelines, or a patient researches a newly prescribed medication, the information AI systems provide shapes decisions about treatment adherence and prescribing behaviour. Pharmaceutical companies that ensure accurate, structured information about their products are available online help ensure AI responses are correct.
(How AI search visibility works)AI visibility also matters for pharmaceutical recruitment, partnerships and investor relations. Researchers evaluating potential collaborators, investors assessing pipeline companies and regulators reviewing submission materials all use AI tools during their due diligence processes.
The life sciences landscape is also becoming more competitive, with biotech startups challenging established pharmaceutical companies. AI visibility allows smaller, innovative companies to be discovered by partners and investors who might otherwise only encounter the major players.
Regulatory constraints are the most significant barrier. Pharmaceutical companies must comply with strict codes of practice that govern how medicines can be described, what claims can be made and how safety information must be presented. These constraints often result in content that is technically compliant but too cautious and generic to be useful for AI citation.
The reliance on scientific publications creates a gap. Much of the authoritative information about a pharmaceutical product exists in peer-reviewed journals, conference abstracts and clinical trial databases. While these are valuable sources, they are not always structured in a way that AI assistants can easily parse and cite.
Medical terminology also creates accessibility challenges. The language used in pharmaceutical communications is necessarily precise, but it differs significantly from the language patients use when asking AI assistants questions about their health and medications.
Pharmaceutical companies should create compliant, structured content that ensures accurate AI representation while meeting regulatory requirements.
Create public pages with approved product information including indications, mechanism of action, administration guidance and safety data presented in clear, structured HTML. This gives AI systems accurate, citable content rather than relying on third-party sources.
Publish educational materials that explain diseases, treatment pathways and therapeutic areas in plain language. This content bridges the gap between technical prescribing information and the questions patients ask AI assistants, while remaining compliant with regulatory guidelines.
Ensure clinical trial registrations and results are available in structured formats on your website, complementing registry databases. AI systems reference trial data when answering queries about treatment evidence, and accessible structured data increases citation accuracy.
Create profiles for key opinion leaders and researchers associated with your therapeutic areas. Named experts with verifiable credentials add authority to your content and are frequently cited by AI systems when answering specialist queries.
Add structured data to your medical and pharmaceutical content identifying the content type, audience (professional or patient), last reviewed date and author credentials. This helps AI systems accurately categorise and assess the reliability of your content.
Yes, within regulatory boundaries. Approved product information, patient leaflets and educational materials about disease areas and treatment pathways can all be published as structured web content. The key is ensuring accuracy, appropriate audience targeting and clear labelling of information type.
Biotech startups should focus on publishing clear descriptions of their technology platform, pipeline status, therapeutic focus areas and team expertise. Creating structured content about the science behind their approach and maintaining up-to-date trial information gives AI systems the material needed to accurately describe and recommend the company to researchers, investors and potential partners.